Abstract 565P
Background
Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this abstract is to analyzed the benefit of the introduction in the clinical practice of a multigenic platform on the management of metastatic colorectal cancer (CRC).
Methods
DNA extraction by BiOstic Tissue DNA Isolation kit from tumor after microdissection (>20% tumoral cells). k-ras exon 2 mutations by Sanger sequencing in 277 CRC, by pyrosequencing (KRAS status, Diatech Pharmacogenetics) in 538 CRC; n-ras and b-raf mutations by pyrosequencing (NRAS and BRAF status, Diatech Pharmacogenetics) only in k-ras wt CRC from 01/2014. K-ras, n-ras, b-raf and pik3ca mutations by Maldi-TOF Mass Spectrometry (MassArray Agena Bioscence) with Myriapod Colon Status (Diatech Pharmacogenetics) in 170 CRC.
Results
The mutations frequencies were 41.5% k-ras by Sanger sequencing; 46.1% k-ras, 4.0% n-ras and 5.3% b-raf by pyrosequencing; 47.6% k-ras, 8.2% n-ras, 7.1% b-raf, 12.3% pik3ca by MassArray. For all genes the change of methodology has improved the diagnostic sensitivity of test. The introduction of multigenic platform allowed the simultaneous analysis of k-ras, n-ras, b-raf and pik3ca mutations in all patients with CRC, avoiding the step by step analysis approach constrained by a single gene methodology. The comparison of technical features is listed in the table.
| Sanger Sequencing** | Pyrosequencing | MassArray | |
|---|---|---|---|
| Amount of DNA | 200 ng | 350 ng | 160 ng |
| Contamination | Likely | Possible | Rare |
| Analytical Sensitivity | 10-20% | 5-7.5% | 2.5-5% (b-raf 10%) |
| Specificity | 100% | 100% | 100% |
| Consumable cost/patient* | 50 euro | 400 euro | 200 euro |
| Hands-on time | 4 h | 4h | 2.5 h |
| Overall time to results from the DNA | 2.5 days | 2.5 days | 1 day |
| Difficulties of data interpretation | Intermediate | Intermediate | Low |
| CE/IVD Validation | No | Yes | Yes |
* Cost determined on the basis of 5 patients/run. **Only k-ras exon 2
Conclusions
The introduction in the routine diagnostics of a multigenic platform is clearly an attractive approach to increase the quality and the rapidity of molecular analysis results, that can be translate in a better clinical management of metastatic colorectal patient.
Clinical trial identification
Legal entity responsible for the study
Humanitas Research Hospital
Funding
National Health System
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract